With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

CagriSema is delivered as a once-weekly subcutaneous injection, like Wegovy and Zepbound, and Novo Nordisk also presented data at ADA on its oral weight-loss candidate amycretin, which combines ...

And in Novo Nordisk’s CagriSema trial, 40% of participants did lose at least 25% of their body weight – just not enough to bump the trial’s overall average result past that benchmark.

Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is "what we expected in this data scenario," as CagriSema weight loss data is not as differentiated compared ...

CagriSema slightly underperformed expectations in the REDEFINE 1 study reported in December, achieving a headline reduction in weight of 22.7% at 68 weeks, which fell short of the 25% that Novo ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that Novo's next-generation CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15. ...

That means the study met its main goal, but those watching the weight-loss drug race closely had pegged their hopes on an average result for CagriSema of at least 25% weight loss, which would set ...